Pathogenesis of anemia during human immunodeficiency virus infection

Journal of Investigative Medicine

Volumn 49, Issue 3, 2001, Pages 225-239

  Semba, Richard D ^a,c   Gray, Glenda E ^b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; INDINAVIR; LAMIVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANEMIA; ANTIMICROBIAL THERAPY; BLOOD TRANSFUSION; CHRONIC DISEASE; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DISEASE COURSE; FOLIC ACID DEFICIENCY; GEOGRAPHIC DISTRIBUTION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON DEFICIENCY; MYCOBACTERIUM AVIUM; OPPORTUNISTIC INFECTION; PARVOVIRUS; PATHOGENESIS; PREVALENCE; RETINOL DEFICIENCY; REVIEW; ANTIRETROVIRAL THERAPY; ATYPICAL MYCOBACTERIOSIS; CLINICAL TRIAL (TOPIC); HUMAN PARVOVIRUS B19; IRON DEFICIENCY ANEMIA; NONHUMAN; PARVOVIRUS INFECTION;

HUMAN IMMUNODEFICIENCY VIRUS; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; PARVOVIRUS;

EID: 0035000316     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/6650.2001.33967     Document Type: Review

References (199)

1. Spivak JL, Bender BS, Quinn TC. Hematologic abnormalities in the acquired immune deficiency syndrome. Am J Med 1984;77:224-228.
2. Polk BF, Fox R, Brookmeyer R, et al. Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men. N Engl J Med 1987;316:61-66.
3. Moore RD. Human immunodeficiency virus infection, anemia, and survival. Clin Infect Dis 1999;29:44-49.
4. Aboulafia DM, Mitsuyasu RT. Hematologic abnormalities in AIDS. Hematol Oncol Clin North Am 1991;5:195-214.
5. Ellaurie M, Burns ER, Rubinstein A. Hematologic manifestations in pediatric HIV infection: Severe anemia as a prognostic factor. Am J Pediatr Hematol Oncol 1990;12:449-453.
6. Barroso J. A review of fatigue in people with HIV infection. J Assoc Nurses AIDS Care 1999;10:42-49.
7. Semba RD, Tang AM. Micronutrients and the pathogenesis of human immunodeficiency virus infection. Br J Nutr 1999;81:181-189.
8. Kreuzer KA, Rockstroh JK. Pathogenesis and pathophysiology of anemia in HIV infection. Ann Hematol 1997;75:179-187.
9. Spivak JL, Barnes DC, Fuchs E. Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989;261:3104-107.
10. Fuchs D, Zangerle R, Artner-Dworzak E, et al. Association between immune activation, changes of iron metabolism, and anaemia in patients with HIV infection. Eur J Hematol 1993;50:90-94.
11. Kravcik S, Toye BW, Fyke K, et al. Impact of Mycobacterium avium complex prophylaxis on the incidence of mycobacterial infections and transfusion-requiring anemia in an HIV-positive population. J Acquir Immun Defic Syndr Hum Retrovirol 1996;13:27-32.
12. Abkowitz JL, Brown KE, Wood RW, Kovach NL, Green SW, Young NS. Clinical relevance of parvovirus B19 as a cause of anemia in patients with human immunodeficiency virus infection. J Infect Dis 1997;176:269-273.
13. Folks TM, Kessler SW, Orenstein JM, Justement JS, Jaffe ES, Fauci AS. Infection and replication of HIV-1 in purified progenitor cells of normal human bone marrow. Science 1988;242:919-922.
14. Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998;91: 1479-1495.
15. Pluda JM, Mitsuya H, Yarchoan R. Hematologic effects of AIDS therapies. Hemat Oncol Clin North Am 1991;5:229-248.
16. Quinn TC. Global burden of the HIV pandemic. Lancet 1996; 348:99-106.
17. Yip R, Dallman PR. Iron. In: Ziegler EE, Filer LJ Jr, eds. Present knowledge in nutrition, 7th ed. Washington, DC: ILSI Press, International Life Sciences Institute; 1996:277-292.
18. Turner BJ, Hauck WW, Fanning TR, Markson LE. Cigarette smoking and maternal-child HIV transmission. J Acquir Immune Defic Syndr Hum Retrovirol 1997;14:327-337.
19. Burns DN, FitzGerald G, Semba RD, et al. Vitamin A deficiency and other nutritional indices during pregnancy in human immunodeficiency virus infection: prevalence, clinical correlates, and outcome. Clin Infect Dis 1999;29:328-334.
20. St Louis ME, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. JAMA 1993;269:2853-2859.
21. Bobat R, Coovadia H, Coutsoudis A, Moodley D. Determinants of mother-to-child transmission of human immunodeficiency virus type 1 infection in a cohort from Durban, South Africa. Pediatr Infect Dis J 1996;15:604-610.
22. Ladner J, Leroy V, Hoffman P, et al. Chorioamnionitis and pregnancy outcome in HIV-infected African women. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18:293-298.
23. Coutsoudis A, Pillay K, Spooner E, Kuhn L, Coovadia HM, South African Vitamin A Study Group. Randomized trial testing the effect of vitamin A supplementation on pregnancy outcomes and early mother-to-child HIV-1 transmission in Durban, South Africa. AIDS 1999;13:1517-1524.
24. John GC, Nduati RW, Mbori-Ngacha D, et al. Genital shedding of human immunodeficiency virus type 1 DNA during pregnancy: Association with immunosuppression, abnormal cervical or vaginal discharge, and severe vitamin A deficiency. J Infect Dis 1997;175:57-62.
25. Meda N, Mandelbrot L, Cartoux M, Dao B, Ouangre A, Dabis F. Anaemia during pregnancy in Burkina Faso, west Africa, 1995-96. DITRAME Study Group Bull World Health Organ 1999;77:916-922.
26. Ramon R, Sawadogo D, Koko FS, et al. Haematological characteristics and HIV status of pregnant women in Abidjan, Côte d'Ivoire, 1995-96. Trans R Soc Trop Med Hyg 1999;93:419-422.
27. Semba RD, Kumwenda N, Hoover DR, et al. Assessment of iron status using plasma transferrin receptor in pregnant women with and without human immunodeficiency virus infection in Malawi. Eur J Clin Nutr 2000;54:872-877.
28. Italian Register for HIV Infection in Children. Features of children perinatally infected with HIV-1 surviving longer than 5 years. Lancet 1994;343:191-195.
29. Adewuyi J, Chitsike I. Haematologic features of the human immunodeficiency virus (HIV) infection in black children in Harare. Cent Afr J Med 1994;40:333-336.
30. Greenberg BL, Semba RD, Schoenbaum EE, Klein RS. Vitamin A deficiency among former and current injecting drug users in Bronx, New York. Nutr Res 1997;17:785-796.
31. Saah AJ, Hoover DR, He Y, Kingsley LA, Phair JP. Multicenter AIDS Cohort Study. Factors influencing survival after AIDS: report from the Multicenter AIDS Cohort Study (MACS). J Acquir Immune Defic Syndr 1994;7:287-295.
32. Swanson CE, Tindall B, Cooper DA, Australian Zidovudine Study Group. Efficacy of zidovudine treatment in homosexual men with AIDS-related complex: Factors influencing development of AIDS, survival, and drug intolerance. AIDS 1994;8:625-634.
33. Van der Werf MJ, van Benthem BHB, van Ameijden AJC. Prevalence, incidence and risk factors of anaemia in HIV-positive and HIV-negative drug users. Addiction 2000;95:383-392.
34. Creagh-Kirk T, Doi P, Andrews E, et al. Survival experience among patients with AIDS receiving zidovudine: Follow-up of patients in a compassionate plea program. JAMA 1988;260:3009-3015.
35. Steinberg JP, Spear JB, Murphy RL, et al. Predictors of outcome in AIDS patients receiving zidovudine. J Acquir Immune Defic Syndr 1989;2:229-234.
36. Swanson CE, Cooper DA, Australian Zidovudine Study Group. Factors influencing outcome of treatment with zidovudine of patients with AIDS in Australia. AIDS 1990;4:749-757.
37. Moore RD, Keruly J, Richman DD, Creagh-Kirk T, Chaisson RE, Zidovudine Epidemiology Study Group. Natural history of advanced HIV disease in patients treated with zidovudine. AIDS 1992;6:671-677.
38. Semba RD, Caiaffa WT, Graham NMH, Cohn S, Vlahov D. Vitamin A deficiency and wasting as predictors of mortality in human immunodeficiency virus-infected injection drug users. J Infect Dis 1995; 171:1196-1202.
39. + lymphocyte count versus clinical severity. J Clin Epidemiol 1996;49:59-65.
40. 3. J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:346-355.
41. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW, and the Adult/Adolescent Spectrum of Disease Group. Epidemiology of anemia in human immunodeficiency virus (HIV)-infected persons: results from the Multistate Adult and Adolescent Spectrum of HIV Disease Surveillance Project. Blood 1998;91:301-308.
42. UNICEF/UNU/WHO/MI. Preventing iron deficiency in women and children. Technical consensus on key issues. Boston International Nutrition Foundation; 1999.
43. Allen LH. Anemia and iron deficiency: effects on pregnancy outcome. Am J Clin Nutr 2000;71(suppl):1280S-1284S.
44. Allen LH. Pregnancy and iron deficiency: Unresolved issues. Nutr Rev 1997;55:91-101.
45. Murphy JF, O'Riordan J, Newcombe RG, et al. Relation of haemoglobin levels in the first and second trimesters to outcome of pregnancy. Lancet 1986;1:992-994.
46. Mueller BU, Tannenbaum S. Pizzo PA. Bone marrow aspirates and biopsies in children with human immunodeficiency virus infection. J Pediatr Hemat Oncol 1996;18:266-271.
47. Van den Broek NR, Letsky EA, White SA, Shenkin A. Iron status in pregnant women: Which measurements are valid? Br J Haematol 1998;103:817-824.
48. Massawe SN, Urassa ENJ, Mmari M, Ronquist G, Lindmark G, Nystrom L. The complexity of pregnancy anemia in Dar-es-Salaam. Gynecol Obstet Invest 1999;47:76-82.
49. Beach RS, Mantero-Atienza E, Shor-Posner G, et al. Specific nutrient abnormalities in asymptomatic HIV-1 infection. AIDS 1992;6: 701-708.
50. Guarino A, Albano F, Tarallo L, et al. Intestinal malabsorption of HIV-infected children: Relationship to diarrhoea, failure to thrive, enteric micro-organisms and immune impairment. AIDS 1993;7:1435-1440.
51. De Vizia B, Poggi V, Connena R, Fiorillo A, Scippa L. Iron absorption and iron deficiency in infants and children with gastrointestinal disease. J Pediatr Gastroenterol Nutr 1992;14:21-26.
52. Castaldo A, Tarallo L, Palomba E, et al. Iron deficiency and intestinal malabsorption in HIV disease. J Pediatr Gastroenterol Nutr 1996;22:359-363.
53. Belitsos PC, Greenson JK, Yardley JH, Sisler JR, Bartlett JG. Association of gastric hypoacidity with opportunistic enteric infections in patients with AIDS. J Infect Dis 1992;166:277-284.
54. Tarimo DS, Killewo JZ, Minjas JN, Msamanga GI. Prevalence of intestinal parasites in adult patients with enteropathic AIDS in northeastern Tanzania. East Afr Med J 1996;73:397-399.
55. Khumalo-Ngwenya B, Luo NP, Chintus C, et al. Gut parasites in HIV-seropositive Zambian adults with diarrhoea. East Afr Med J 1994; 71:379-383.
56. Gupta S, Imam A, Licorish K. Serum ferritin in acquired immune deficiency syndrome. J Clin Lab Immunol 1986;20:11-13.
57. Boelaert JR, Weinberg GA, Weinberg ED. Altered iron metabolism in HIV infection: Mechanisms, possible consequences, and proposals for management. Infect Agents Dis 1996;5:36-46.
58. Savarino A, Pescarmona GP, Boelaert JR. Iron metabolism and HIV infection: Reciprocal interactions with potentially harmful consequences? Cell Biochem Funct 1999;17:279-287.
59. Costagliola DG, Montalembert M. Lefrère JJ, et al. Dose of desferrioxamine and evolution of HIV-1 infection in thalassaemic patients. Br J Haematol 1994;87:849-852.
60. Sahli Y, Castagliola D, Rebulla P, et al. Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients. J Acquir Immune Defic Hum Retrovirol 1998;18:473-478.
61. Salmon-Céron D, Fontbonne A, Saba J, et al. Lower survival in AIDS patients receiving dapsone compared with aerosolized pentamidine for secondary prophylaxis of Pneumocystis carinii pneumonia. J Infect Dis 1995;172:656-64.
62. Vildé JL, Salmon-Céron D. Reply [letter]. J Infect Dis 1996;173: 1045-1046.
63. Jacobus DP. Randomization to iron supplementation of patients with advanced human immunodeficiency virus disease: An inadvertent but controlled study with results important for patient care. J Infect Dis 1996;173:1044-1045.
64. Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HSLM, Marx JJM, van Asbeck BS. Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxime, deferiprone, and bleomycin. J Infect Dis 2000;181: 484-490.
65. Delanghe JR, Langlois MR, Boelaert JR, et al. Haptoglobin polymorphism, iron metabolism, and mortality in HIV infection. AIDS 1998;12:1027-1032.
66. De Monyé C, Karcher DS, Boelaert JR, Gordeuk VR. Bone marrow macrophage iron grade and survival of HIV-seropositive patients. AIDS 1999;13:375-380.
67. Bogden JD, Baker H, Frank O, et al. Micronutrient status and human immunodeficiency virus (HIV) infection. Ann N Y Acad Sci 1990;587:189-195.
68. Skurnick JH, Bogden JD, Baker H, et al. Micronutrient profiles in HIV-1-infected heterosexual adults. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:75-83.
69. Coodley G, Girard DE. Vitamins and minerals in HIV infection. J Gen Intern Med 1991;6:472-479.
70. 12, and folate levels and human immunodeficiency virus type 1 (HIV-1) disease progression. J Nutr 1997;127: 345-351.
71. 12, and HIV infection. Lancet 1990;335:1401-1402.
72. Beach RS, Mantero-Atienza E, Eisdorfer C, Fordyce-Baum MK. Altered folate metabolism in early HIV infection. JAMA 1988;259:518.
73. Tilkian SM, Lefevre G, Coyle C. Altered folate metabolism in early HIV infection. JAMA 1988;259:3128-3129.
74. Revell P, O'Doherty MJ, Tang A, Savidge GF. Folic acid absorption in patients infected with the human immunodeficiency virus. J Intern Med 1991;230:227-231.
75. Fishman SM, Christian P, West KP Jr. The role of vitamins in the prevention and control of anemia. Public Health Nutr 2000;3:125-150.
76. Burkes RL, Cohen H, Krailo M, Sinow RM, Carmel R. Low serum cobalamin levels occur frequently in the acquired immune deficiency syndrome and related disorders. Eur J Haematol 1987;38: 141-147.
77. 12 malabsorption in patients with acquired immunodeficiency syndrome. Arch Intern Med 1989;149: 2039-2041.
78. 12 levels in patients infected with the human immunodeficiency virus. Am J Hematol 1995;49: 318-322.
79. 12 and transcobalamin levels in early HIV disease. Am J Hematol 1994;47:167-171.
80. 12 metabolism in human immunodeficiency virus infection: Association with neurological dysfunction. Arch Neurol 1991;48: 312-314.
81. 12 metabolism in early HIV infection. Can J Neurol Sci 1995;22:43-46.
82. 12 deficiency in early human immunodeficiency virus-1 infection. Arch Intern Med 1991;151:1019-1020.
83. 12 (cobalamin) absorption in patients with AIDS. Am J Hematol 1990;34:132-139.
84. Remacha AF, Montagud M, Cadafalch J, Riera A, Martino R, Gimferrer E. Vitamin B12 transport proteins in patients with HIV-1 infection and AIDS. Haematologica 1993;78:84-88.
85. Modigliani R, Bories C, Le Charpentier Y, et al. Diarrhoea and malabsorption in acquired immune deficiency syndrome: A study of four cases with special emphasis on opportunistic protozoan infestations. Gut 1985;26:179-187.
86. Kapembwa MS, Bridges C, Joseph AEA, Fleming SC, Batman P, Griffin GE. Ileal and jejunal absorptive function in patients with AIDS and enterococcidial infection. J Infect 1990;21:43-45.
87. 12 in HIV-infected patients with chronic diarrhea. Dig Dis Sci 1994;39:2159-2162.
88. Goodgame RW, Kimball K, Ou CN, et al. Intestinal function and injury in acquired immunodeficiency syndrome-related cryptosporidiosis. Gastroenterology 1995;108:1075-1082.
89. Herzlich BC, Schiano TD, Moussa Z, et al. Decreased intrinsic factor secretion in AIDS: Relation to parietal cell acid secretory capacity and vitamin B12 malabsorption. Am J Gastroenterol 1992;87:1781-1787.
90. 12, and folate levels and human immunodeficiency virus type 1 (HIV-1) disease progression. J Nutr 1997;127: 345-351.
91. Semba RD, Muhilal, West KP Jr, et al. Effect of vitamin A supplementation on hematological indicators of iron metabolism and nutritional status in children. Nutr Res 1992;12:469-478.
92. Bloem MW. Interdependence of vitamin A and iron: An important association for programmes of anaemia control. Proc Nutr Soc 1995;54:501-508.
93. Okano M, Masuda S, Narita H, et al. Retinoic acid up-regulates erythropoietin production in hepatoma cells and in vitamin A-depleted rats. FEBS Lett 1994;349:229-233.
94. Jelkmann W, Pagel H, Hellwig T, Fandrey J. Effects of antioxidant vitamins on renal and hepatic erythropoietin production. Kidney Int 1997;51:497-501.
95. Semba RD. Vitamin A and human immunodeficiency virus infection. Proc Nutr Soc 1997;56:459-469.
96. Suharno D, West CE, Muhilal, Karyadi D, Hautvast JG. Supplementation with vitamin A and iron for nutritional anaemia in pregnant women in West Java, Indonesia. Lancet 1993;342:1325-1328.
97. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639-1647.
98. Cash JM, Sears DA. The anemia of chronic disease: Spectrum of associated disease in a series of unselected hospitalized patients. Am J Med 1989;87:638-644.
99. Spivak JL. The blood in systemic disorders. Lancet 2000;355: 1707-1712.
100. Cartwright GE. The anemia of chronic disorders. Semin Hematol 1966;3:351-375.
101. Erslev AJ, Wilson J, Caro J. Erythropoietin titers in anemic, nonuremic patients. J Lab Clin Med 1987;109:429-433.
102. Erslev AJ. Erythropoietin. N Engl J Med 1991;324:1339-1344.
103. Spivak JL, Barnes DC, Fuchs E, Quinn TC. Serum immunoreactive erythropoietin in HIV-infected patients. JAMA 1989;261: 3104-3107.
104. Rarick MU, Loureiro C, Groshen S, et al. Serum erythropoietin titers in patients with human immunodeficiency virus (HIV) infection and anemia. J Acquir Immune Defic Syndr 1991;4:593-597.
105. Camacho J, Poveda F, Zamorano AF, Valencia ME, Vásquez JJ, Arnalich F. Serum erythropoietin levels in anaemic patients with advanced human immunodeficiency virus infection. Br J Haematol 1992; 82:608-614.
106. Kreuzer KA, Rockstroh JK, Jelkmann W, Theisen A, Spengler U, Sauerbruch T. Inadequate erythropoietin response to anaemia in HIV patients: Relationship to serum levels of tumour necrosis factor-alpha, interleukin-6, and their soluble receptors. Br J Haematol 1997;96: 235-239.
107. Murphy M, Perussia B, Trinchieri G. Effects of recombinant tumor necrosis factor, lymphotoxin, and immune interferon on proliferation and differentiation of enriched hematopoietic precursor cells. Exp Hematol 1988;16:131-138.
108. Fuchs D, Reibnegger G, Werner ER, Vinazzer H, Wachter H. Low haemoglobin in haemophilia children is associated with chronic immune activation. Acta Haematol 1991;85:62-65.
109. Sipsas NV, Kokori SI, Ioannidis JPA, Kyriaki D, Tzioufas AG, Kordossis T. Circulating autoantibodies to erythropoietin are associated with human immunodeficiency virus type 1-related anemia. J Infect Dis 1999;180:2055-2157.
110. Barosi G. Inadequate erythropoietin response to anemia: Definition and clinical relevance. Ann Hematol 1994;68:215-223.
111. Wang Z, Goldberg MA, Scadden DT. HIV-1 suppresses erythropoietin production in vitro. Exp Hematol 1993;21:683-688.
112. Fischl M, Galpin JE, Levine JD, et al. Recombinant human erythropoietin for patients with AIDS treated with zidovudine. N Engl J Med 1990;322:1488-1493.
113. Henry DH, Beall GN, Benson CA, et al. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy: Overview of four clinical trials. Ann Intern Med 1992;117:739-748.
114. Phair JP, Abels RI, McNeill MV, Sullivan DJ. Recombinant human erythropoietin treatment: Investigational new drug protocol for the anemia of the acquired immunodeficiency syndrome: Overall results. Arch Intern Med 1993;153:2669-2675.
115. Revicki DA, Brown RE, Henry DH, McNeill MC, Rios A, Watson T. Recombinant human erythropoietin and health-related quality of life of AIDS patients with anemia. J Acquir Immune Defic Syndr 1994;7:474-484.
116. Goodnough LT, Anderson KC, Kurtz S, et al. Indications and guidelines for the use of hematopoietic growth factors. Transfusion 1993;33:944-959.
117. Zuccotti GV, Flumine P, Locatelli V, Banderali G, Riva E. Growth factors and HIV-infection in children. J Int Med Res 1993;21: 342-345.
118. Havlik JA Jr, Horsburgh CR Jr, Metchock B, Williams PP, Fann SA, Thompson SE. Disseminated Mycobacterium avium complex infection: Clinical identification and epidemiological trends. J Infect Dis 1992;165:577-580.
119. Shafran SD. Prevention and treatment of disseminated Mycobacterium avium complex infection in human immunodeficiency virus-infected individuals. Int J Infect Dis 1998;3:39-47.
120. Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis 1992;165:1082-1085.
121. Horsburgh CR Jr. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991;324: 1332-1338.
122. Sathe SS, Gascone P, Lo W, Pinto R, Reichman LB. Severe anemia is an important negative predictor for survival with disseminated Mycobacterium avium-intracellulare in acquired immunodeficiency syndrome. Am Rev Respir Dis 1990;142:1306-1312.
123. Wallace JM, Hannah JB. Mycobacterium avium complex infection in patients with the acquired immunodeficiency syndrome: A clinicopathological study. Chest 1988;93:926-932.
124. Nightingale SD, Cameron DW, Gordin FM, et al. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med 1993;329:828-833.
125. Gascón P, Sathe SS, Rameshwar P. Impaired erythropoiesis in the acquired immunodeficiency syndrome with disseminated Mycobacterium avium complex. Am J Med 1993;94:41-48.
126. Ellaurie M, Rubinstein A. Elevated tumor necrosis factor-alpha in association with severe anemia in human immunodeficiency virus infection and Mycobacterium avium intracellulare infection. Pediatr Hematol Oncol 1995;12:221-230.
127. Gardener TD, Flanagan P, Dryden MS, Costello C, Shanson DC, Gazzard BG. Disseminated Mycobacterium avium-intracellulare infection and red cell hypoplasia in patients with the acquired immune deficiency syndrome. J Infect 1988;16:135-140.
128. Mir N, Costello C. Luckit J, Lindley R. HIV-disease and bone marrow changes: A study of 60 cases. Eur J Haematol 1989;42:339-343.
129. Anderson MJ. Parvoviruses as agents of human disease. Prog Med Virol 1987;34:55-69.
130. Brown T, Anand A, Ritchie LD, Clewley JP, Reid TMS. Intrauterine parvovirus infection associated with hydrops fetalis. Lancet 1984;2:1033-1034.
131. Pont J, Puchhammer-Stöckl E, Chott A, et al. Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection. Br J Haematol 1992;80:160-165.
132. Frickhofen N, Abkowitz JL, Safford M, et al. Persistent B19 parvovirus infection in patients infected with human immunodeficiency virus type 1 (HIV-1): A treatable cause of anemia in AIDS. Ann Intern Med 1990;113:926-933.
133. Gyllensten K, Sönnerborg A, Jorup-Rönström C, Halvarsson M, Yun Z. Parvovirus B19 infection in HIV-1 infected patients with anemia. Infection 1994;22:356-358.
134. Leads from the MMWR. Risks associated with human parvovirus B19 infection. JAMA 1989;261:1406-1408, 1555-63.
135. Cohen BJ, Mortimer PP, Pereira MS. Diagnostic assays with monoclonal antibodies for the human serum parvovirus-like virus (SPLV). J Hygiene 1983;91:113-130.
136. Liu W, Ittmann M, Liu J, et al. Human parvovirus B19 in bone marrows from adults with acquired immunodeficiency syndrome: A comparative study using in situ hybridization and immunohistochemistry. Hum Pathol 1997;28:760-766.
137. Chernak E, Dubin G, Henry D, et al. Infection due to parvovirus B19 in patients infected with human immunodeficiency virus. Clin Infect Dis 1995;20:170-173.
138. Van Elsacker-Neile AMW, Kroon FP, van der Ende ME, Salimans MMM, Spaan WJM, Kroes ACM. Prevalence of parvovirus B19 infection in patients infected with human immunodeficiency virus. Clin Infect Dis 1996;23:1255-1260.
139. Raguin G, Leruez-Ville M, Gregoire V, Deplanche M, Leport C, Morinet F, Vilde JL. Low prevalence of active parvovirus B19 infection in HIV-infected patients. Eur J Clin Microbiol Infect Dis 1997;16: 760-762.
140. Naides SJ, Howard EJ, Swack NS, True CA, Stapleton JT. Parvovirus B19 infection in human immunodeficiency virus type 1-infected persons failing or intolerant to zidovudine therapy. J Infect Dis 1993;168:101-105.
141. Fuller A, Moaven L, Spelman D, Spicer WJ, Wraight H, Curtis D, Leydon J, Doultree J, Locarnini S. Parvovirus B19 in HIV infection: A treatable cause of anemia. Pathology 1996;28:277-280.
142. Ramratnam B, Gollerkeri A, Schiffman FJ, Rintels P, Flanigan TP. Management of persistent B19 parvovirus infection in AIDS. Br J Haematol 1995;91:90-92.
143. Martins A, Costa A, Oliveira MJ, Rodrigues M, Ribeiro AP, Silvestre F, Reis A. Pure red cell aplasia due to persistent B19 parvovirus infection in patient infected with human immunodeficiency virus type 1: Recovery with alpha-interferon therapy. Sangre (Barc) 1998;43:67-69.
144. Mylonakis E, Dickinson BP, Mileno MD, et al. Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: Complete remission associated with highly active anti-retroviral therapy. Am J Hematol 1999;60:164-166.
145. Anderson MJ, Higgins PG, Davis LR, et al. Experimental parvoviral infection in humans. J Infect Dis 1985;152:257-265.
146. Osborne BM, Guarda LA, Butler JJ. Bone marrow biopsies in patients with the acquired immunodeficiency syndrome. Hum Pathol 1984;15:1048-1053.
147. Castella A, Croxson TS, Mildvan D, Witt DH, Zalusky R. The bone marrow in AIDS: A histologic, hematologic, and microbiologic study. Am J Clin Pathol 1985;84:425-432.
148. Schneider DR, Picker LJ. Myelodysplasia in the acquired immune deficiency syndrome. Am J Clin Pathol 1985;84:144-152.
149. Zon LI, Arkin C, Groopman JE. Haematologic manifestations of the human immune deficiency virus (HIV). Br J Haematol 1987;66: 251-256.
150. Treacy M, Lai L, Costello C, Clark A. Peripheral blood and bone marrow abnormalities in patients with HIV related disease. Br J Haematol 1987;65:289-294.
151. Bagnara GP, Zauli G, Giovannini M, Re MC, Furlini G, La Placa M. Early loss of circulating hemopoietic progenitors in HIV-1-infected subjects. Exp Hematol 1990;18:426-430.
152. Cleveland RP, Liu YC. CD4 expression by erythroid precursor cells in human bone marrow. Blood 1996;87:2275-2282.
153. Lee B, Ratajczak J, Doms RW, Gewirtz AM, Ratajczak MZ. Coreceptor/chemokine receptor expression on human hematopoietic cells: Biological implications for human immunodeficiency virus-type 1 infection. Blood 1999;93:1145-1156.
154. Chelucci C, Casella I, Federico M, et al. Lineage-specific expression of human immunodeficiency virus (HIV) receptor/coreceptors in differentiating hematopoietic precursors: Correlation with susceptibility to T- and M-tropic HIV and chemokine-mediated HIV resistance. Blood 1999;94:1590-1600.
155. Furlini G, Vignoli M, Ramazotti E, Re MC, Visani G, La Placa M. A concurrent human herpesvirus-6 infection renders two human hematopoietic progenitor (TF-1 and KG-1) cell lines susceptible to human immunodeficiency virus type-1. Blood 1996;87:4737-4745.
156. Molina JM, Scadden DT, Sakaguchi M, Fuller B, Woon A, Groopman JE. Lack of evidence for infection of or effect on growth of hematopoietic progenitor cells after in vivo or in vitro exposure to human immunodeficiency virus. Blood 1990;76:2476-2481.
157. Steinberg HN, Crumpacker CS, Chatis PA. In vitro suppression of normal human bone marrow progenitor cells by human immunodeficiency virus. J Virol 1991;65:1765-1769.
158. + cells. Ann N Y Acad Sci 1991;628:273-279.
159. +) hematopoietic progenitor cells. Arch Virol 1992;122:271-280.
160. Cen D, Zauli G, Szarnicki R, Davis BR. Effect of different human immunodeficiency virus type-1 (HIV-1) isolates on long-term bone marrow haemopoiesis. Br J Haematol 1993;85:596-602.
161. Neal TF, Holland HK, Baum CM, Villinger F, Ansari AA, Saral R, Wingard JR, Fleming WH. CD34+ progenitor cells from asymptomatic patients are not a major reservoir for human immunodeficiency virus-1. Blood 1995;86:1749-1756.
162. + cells to human immunodeficiency virus type 1 does not influence the expansion and proliferation of hematopoietic progenitors in vitro. Blood 1996;88:130-137.
163. Koka PS, Jamieson BD, Brooks DG, Zack JA. Human immunodeficiency virus type 1-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J Virol 1999;73: 9089-9097.
164. Davis BR, Schwartz DH, Marx JC, et al. Absent or rare human immunodeficiency virus infection of bone marrow stem/progenitor cells in vivo. J Virol 1991;65:1985-1990.
165. +) cells in AIDS patients. J Infect Dis 1992;166: 710-716.
166. Louache F, Henri A, Bettaieb A, et al. Role of human immunodeficiency virus replication in defective in vitro growth of hematopoietic progenitors. Blood 1992;80:2991-2999.
167. Shen H, Cheng T, Preffer FI, et al. Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression. J Virol 1999;73:728-737.
168. Weichold FF, Zella D, Barabitskaja O, et al. Neither human immunodeficiency virus-1 (HIV-1) nor HIV-2 infects most-primitive human hematopoietic stem cells as assessed in long-term bone marrow cultures. Blood 1998;91:907-915.
169. Esser R, Glienke W, Von Briesen H, Rubsamen-Waigmann H, Andreesen R. Differential regulation of proinflammatory and hematopoietic cytokines in human macrophages after infection with human immunodeficiency virus. Blood 1996;88:3474-3481.
170. Scadden DT, Zeira M, Woon A, et al. Human immunodeficiency virus infection of human bone marrow stromal fibroblasts. Blood 1990; 76:317-322.
171. Moses AV, Williams S, Heneveld ML, et al. Human immunodeficiency virus infection of bone marrow endothelium reduces induction of stromal hematopoietic growth factors. Blood 1996;87:919-925.
172. Maciejewski JP, Weichold FF, Young NS. HIV-1 suppression of hematopoiesis in vitro mediated by envelope glycoprotein and TNF-alpha. J Immunol 1994;153:4303-4310.
173. Levine AM, Meyer PR, Begandy MK, et al. Development of B-cell lymphoma in homosexual men. Clinical and immunologic findings. Ann Intern Med 1984;100:7-13.
174. Ziegler JL, Drew WL, Miner RC, et al. Outbreak of Burkitt's-like lymphoma in homosexual men. Lancet 1982;2:631-633.
175. Sirisanthana V, Sirisanthana T. Disseminated Penicillium marneffei infection in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1995;14:935-940.
176. Supparatpinyo K, Khamwan C, Baosoung V, Nelson KE, Sirisanthana T. Disseminated Penicillium marneffei infection in Southeast Asia. Lancet 1994;344:110-113.
177. Little BJ, Spivak JL, Quinn TC, Mann RB. Kaposi's sarcoma with bone marrow involvement: Occurrence in a patient with acquired immunodeficiency syndrome. Am J Med Sci 1986;292:44-46.
178. Prins JM, Sol CJ, Renwick N, Goudsmit J, Veenstra J, Reiss P. Favourable effect of chemotherapy on clinical symptoms and human herpesvirus-8 DNA load in a patient with Kaposi's sarcoma presenting with fever and anemia. Eur J Clin Microbiol Infect Dis 1999;18: 499-502.
179. Mildvan D, Mathur U, Enlow RW, et al. Opportunistic infections and immune deficiency in homosexual men. Ann Intern Med 1982;96:700-704.
180. Pasternak J, Bolivar R. Bone marrow examination and culture in the diagnosis of acquired immunodeficiency syndrome. Arch Intern Med 1983;143:1495.
181. Heyman MR, Rasmussen P. Pneumocystis carinii involvement of the bone marrow in acquired immunodeficiency syndrome. Am J Clin Pathol 1987;87:780-783.
182. Allen S, van de Perre P, Serufilira A, et al. Human immunodeficiency virus and malaria in a representative sample of childbearing women in Kigali, Rwanda. J Infect Dis 1991;164:67-71.
183. Hane AA, Thiam D, Cissokho S, et al. Anomalies de l'hémogramme et immundépression dans l'association VIH/sida-tuberculose pulmonaire [Hemato-immunological abnormalities in tuberculosis and HIV infection in Senegal]. Bull Soc Pathol Exot 1999;92: 161-163.
184. Bell WR, Chulay JD, Feinberg JE. Manifestations resembling thrombotic microangiopathy in patients with advanced human immunodeficiency virus (HIV) disease in a cytomegalovirus prophylaxis trial (ACTG 204). Medicine 1997;76:369-380.
185. Viale P, Pagani L, Alberici F. Clinical features and prognostic factors of HIV-associated thrombotic microangiopathies. Eur J Haematol 1998;60:262-263.
186. Turner ME, Kher K, Rakusan T. et al. A typical hemolytic uremic syndrome in human immunodeficiency virus-1-infected children. Pediatr Nephrol 1997;11:161-163.
187. Peraldi MN, Maslo C, Akposso K, Mougenot B, Rondeau E, Sraer JD. Acute renal failure in the course of HIV infection: A single-institution retrospective study of ninety-two patients and sixty renal biopsies. Nephrol Dial Transplant 1999;14:1578-1585.
188. Gadallah MF, El-Shahawy MA, Campese VM, Todd JR, King JW. Disparate prognosis of thrombotic microangiopathy in HIV-infected patients with and without AIDS. Am J Nephrol 1996;16:466-450.
189. Richman DD, Fischl MA, Grieco MH, et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. N Engl J Med 1987;317:192-197.
190. Shaffer N, Chuachoowong R. Mock PA, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok. Thailand: A randomised controlled trial. Bangkok Collaborative Perinatal HIV Transmission Study Group Lancet 1999;353:773-780.
191. Wiktor SZ, Ekpini E, Karon JM, et al. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan. Cote d'Ivoire: A randomised trial. Lancet 1999;353:781-785.
192. Dabis F, Msellati P, Meda N. et al. 6-month efficacy, tolerance, and acceptability of a short regiment of oral zidovudine to reduce vertical transmission of HIV in breastfed children in Cote d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial. DITRAME Study Group Diminution de la Transmission Mere-Enfant Lancet 1999; 353:786-792.
193. Silverman NS, Watts DH, Hitti J, et al. Initial multicenter experience with double nucleoside therapy for human immunodeficiency virus infection during pregnancy. Infect Dis Obstet Gynecol 1998;6: 237-243.
194. Tseng A, Conly J, Fletcher D, Keystone D, Salit I, Walmsley S. Precipitous declines in hemoglobin levels associated with combination zidovudine and lamivudine therapy. Clin Infect Dis 1998;27:908-909.
195. Hester EK, Peacock JR Jr. Profound and unanticipated anemia with lamivudine-zidovudine combination therapy in zidovudine-experienced patients with HIV infection. AIDS 1998;12:439-440.
196. Prazuck T, Semaille C, Roques S. Fatal acute hemolysis in an AIDS patient treated with indinavir. AIDS 1998;12:531-533.
197. Morrison-Griffiths S, Newman M, O'Mahony C, Pirmohamed M. Haemolytic anaemia associated with indinavir. Postgrad Med J 1999; 75:313-315.
198. Anonymous. Antiviral briefs: Ritonavir and anemia in women. AIDS Patient Care STDS 2000;14:101-102.
199. Mylonakis E, Dickinson B, Feller A, et al. Combination antiretroviral therapy including a protease inhibitor eliminated the transfusion requirements of HIV-infected individuals with anemia of chronic disease. J Acquir Immune Defic Syndr Human Retrovirol 1998;19:306-307.